Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

BioVentrix Revivent TC™ System Clinical Study

NCT02931240 · View on ClinicalTrials.gov ↗

Study Summary

A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocation ratio. This study will include 126 patients of which 84 patients will be treated with the investigational device and 42 patients will be included in an active control group.

Interventions

  • DEVICE Revivent TC

Study Locations (20)

California

  • Ronald Regan UCLA Medical Center — Los Angeles
  • University of California, San Francisco — San Francisco
  • Los Robles Hospital & Medical Center — Thousand Oaks

Georgia

  • Emory University Hospital Midtown — Atlanta
  • WellStar Health System — Marietta

New York

  • Mount Sinai Hospital — New York
  • New York Presbyterian Hospital — New York

Pennsylvania

  • UPMC Pinnacle — Harrisburg
  • Penn State Health Milton S. Hershey Medical Center — Hershey

Arizona

  • University of Arizona College of Medicine - Phoenix Banner University Medicine Heart Institute — Phoenix

Florida

  • Baptist Hospital of Maimi — Miami

Illinois

  • Memorial Medical Center — Springfield

Louisiana

  • Terrebonne General Medical Center — Houma

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2017-08-29
Est. Completion 2027-06-30
Phase NA

Sponsor

BioVentrix

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02931240

The ClinicalTrials.gov registry entry for NCT02931240 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioVentrix, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Ventricular Dysfunction, Left appearing as the primary indexed condition, and to 1 intervention — of which Revivent TC is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02931240 reports 20 study locations spanning 15 distinct geographic areas — top geographies include California, Georgia, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02931240 about?

NCT02931240 is a clinical study titled "BioVentrix Revivent TC™ System Clinical Study". A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocation ratio. This study will include 126 patients of which 84 patients will be treated with the investigational device and 42 patients will be included in...

What is the current status of trial NCT02931240?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 126 participants. The study started on 2017-08-29. Estimated completion is 2027-06-30.

What conditions does trial NCT02931240 study?

This clinical trial studies the following conditions: Ventricular Dysfunction, Left. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02931240?

The interventions under investigation include: Revivent TC (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02931240?

This trial is sponsored by BioVentrix, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02931240 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial